Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iradimed (IRMD) Long-Term Deferred Tax (2016 - 2026)

Iradimed has reported Long-Term Deferred Tax over the past 13 years, most recently at $231000.0 for Q1 2026.

  • Quarterly Long-Term Deferred Tax fell 91.42% to $231000.0 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $231000.0 through Mar 2026, down 91.42% year-over-year, with the annual reading at $94000.0 for FY2025, 96.67% down from the prior year.
  • Long-Term Deferred Tax was $231000.0 for Q1 2026 at Iradimed, up from $94000.0 in the prior quarter.
  • Over five years, Long-Term Deferred Tax peaked at $2.8 million in Q4 2024 and troughed at $94000.0 in Q4 2025.
  • The 5-year median for Long-Term Deferred Tax is $1.8 million (2023), against an average of $1.6 million.
  • Year-over-year, Long-Term Deferred Tax surged 202.88% in 2023 and then plummeted 96.67% in 2025.
  • A 5-year view of Long-Term Deferred Tax shows it stood at $700867.0 in 2022, then surged by 202.88% to $2.1 million in 2023, then surged by 32.84% to $2.8 million in 2024, then plummeted by 96.67% to $94000.0 in 2025, then skyrocketed by 145.74% to $231000.0 in 2026.
  • Per Business Quant, the three most recent readings for IRMD's Long-Term Deferred Tax are $231000.0 (Q1 2026), $94000.0 (Q4 2025), and $2.4 million (Q3 2025).